Citations

Clear

66 citation(s) found for "Morrey, Mark".

Effectiveness of rosiglitazone in reducing flexion contracture in a rabbit model of arthrofibrosis with surgical capsular release
Arsoy, Diren , Riester, Scott M. , Wijnen, André J. van , Morrey, B.F. , Barlow, Jonathan D. , Morrey, Mark E. , Hartzler, Robert U. , Sánchez‐Sotelo, Joaquín , Abdel, Matthew P. , van Wijnen, Andre J

Mayo Clinic

Bone & Joint Research | January 27, 2016 | Volume: 5 | Issue: 1 | Pages: 11-17

10.1302/2046-3758.51.2000593 | PMID 26813567 Get It

Aims Animal models have been developed that allow simulation of post-traumatic joint contracture. One such model involves contracture-forming surgery followed by surgical capsular release. This model allows testing of antifibrotic agents, such as rosiglitazone. Methods A total of 20 rabbits underwent contracture-forming surgery. Eight weeks later, the animals underwent a surgical capsular release. Ten animals received rosiglitazone (intramuscular initially, then orally). The animals were sacrificed following 16 weeks of free cage mobilisation. The joints were tested biomechanically, and the posterior capsule was assessed histologically and via genetic microarray analysis. Results There was no significant difference in post-traumatic contracture between the rosiglitazone and control groups (33° (standard deviation (sd) 11) vs 37° (sd14), respectively; p = 0.4). There was no difference in number or percentage of myofibroblasts. Importantly, there were ten genes and 17 pathways that were significantly modulated by rosiglitazone in the posterior capsule. Discussion Rosiglitazone significantly altered the genetic expression of the posterior capsular tissue in a rabbit model, with ten genes and 17 pathways demonstrating significant modulation. However, there was no significant effect on biomechanical or histological properties. Cite this article: M. P. Abdel. Effectiveness of rosiglitazone in reducing flexion contracture in a rabbit model of arthrofibrosis with surgical capsular release: A biomechanical, histological, and genetic analysis. Bone Joint Res 2016;5:11–17. doi: 10.1302/2046-3758.51.2000593
Quantitative assessment of barriers to the clinical development and adoption of cellular therapies: A pilot study
Davies, Benjamin M. , Rikabi, Sarah , French, Anna , Pinedo‐Villanueva, Rafael , Wartolowska, Karolina , Judge, Andrew , MacLaren, Robert E. , Mathur, Anthony , Williams, David , Wall, Ivan , Birchall, Martin , Reeve, Brock , Barker, Richard , Cui, Zhanfeng , Bure, Kim, Snyder, Evan Y., Carr, Andrew , Morrey, Mark E. , Atala, Anthony , Furniss, Dominic , Karp, Jeffrey M. , Price, Andrew James , Brindley, David A.

Mayo Clinic

Journal of Tissue Engineering | September 23, 2014 | Volume: 5 | Issue: No issue available | Pages: No page available

10.1177/2041731414551764 | PMID 25383173 Get It

There has been a large increase in basic science activity in cell therapy and a growing portfolio of cell therapy trials. However, the number of industry products available for widespread clinical use does not match this magnitude of activity. We hypothesize that the paucity of engagement with the clinical community is a key contributor to the lack of commercially successful cell therapy products. To investigate this, we launched a pilot study to survey clinicians from five specialities and to determine what they believe to be the most significant barriers to cellular therapy clinical development and adoption. Our study shows that the main concerns among this group are cost-effectiveness, efficacy, reimbursement, and regulation. Addressing these concerns can best be achieved by ensuring that future clinical trials are conducted to adequately answer the questions of both regulators and the broader clinical community.
Intra-articular decorin influences the fibrosis genetic expression profile in a rabbit model of joint contracture
Grill, Diane E. , Kolbert, Christopher P., An, Kai‐Nan , Steinmann, Scott P. , Morrey, B.F. , Abdel, Matthew P. , Morrey, Mark E. , Barlow, Jonathan D. , Sánchez‐Sotelo, Joaquín

Mayo Clinic

Bone & Joint Research | March 27, 2014 | Volume: 3 | Issue: 3 | Pages: 82-88

10.1302/2046-3758.33.2000276 | PMID 24671942 Get It

Objectives The goal of this study was to determine whether intra-articular administration of the potentially anti-fibrotic agent decorin influences the expression of genes involved in the fibrotic cascade, and ultimately leads to less contracture, in an animal model. Methods A total of 18 rabbits underwent an operation on their right knees to form contractures. Six limbs in group 1 received four intra-articular injections of decorin; six limbs in group 2 received four intra-articular injections of bovine serum albumin (BSA) over eight days; six limbs in group 3 received no injections. The contracted limbs of rabbits in group 1 were biomechanically and genetically compared with the contracted limbs of rabbits in groups 2 and 3, with the use of a calibrated joint measuring device and custom microarray, respectively. Results There was no statistical difference in the flexion contracture angles between those limbs that received intra-articular decorin versus those that received intra-articular BSA (66° vs 69°; p = 0.41). Likewise, there was no statistical difference between those limbs that received intra-articular decorin versus those who had no injection (66° vs 72°; p = 0.27). When compared with BSA, decorin led to a statistically significant increase in the mRNA expression of 12 genes (p < 0.01). In addition, there was a statistical change in the mRNA expression of three genes, when compared with those without injection. Conclusions In this model, when administered intra-articularly at eight weeks, 2 mg of decorin had no significant effect on joint contractures. However, our genetic analysis revealed a significant alteration in several fibrotic genes. Cite this article: Bone Joint Res 2014;3:82–8.
The Implementation of Novel Collaborative Structures for the Identification and Resolution of Barriers to Pluripotent Stem Cell Translation
French, Anna , Suh, Jane, Roberts, Mackenna, Davies, Benjamin M. , Pinedo‐Villanueva, Rafael , Wartolowska, Karolina , Rooke, Kelly, Kramm, Anneke, Judge, Andrew , Chandra, Amit , Hurley, Hannah, Grover, Liam M. , Bingham, Ian, Siegel, Bernard, Rattley, Matt S., Buckler, R. Lee, McKeon, David, Krumholz, Katie, Hook, Lilian , Rikabi, Sarah , Pigott, Rosie, Morys-Carter, Megan M. , Sabokbar, Afsie, Titus, Emily, Laâbi, Yacine, Zahkia, Raymond, Sipp, Douglas , Horne, Robert , Bravery, Christopher A., Williams, David , Wall, Ivan , Snyder, Evan Y., Barker, Richard , Bure, Kim, Reeve, Brock , Brindley, David A. , Morrey, Mark E. , May, Michael E , Lemaı̂tre, Gilles , Karp, Jeffrey M. , Carr, Andrew Jonathan , Horne, Rob

Mayo Clinic

Stem Cells and Development | December 4, 2013 | Volume: 22 | Issue: 1_suppl | Pages: 63-72

10.1089/scd.2013.0403 | PMID 24304079 Get It

Increased global connectivity has catalyzed technological development in almost all industries, in part through the facilitation of novel collaborative structures. Notably, open innovation and crowd-sourcing—of expertise and/or funding—has tremendous potential to increase the efficiency with which biomedical ecosystems interact to deliver safe, efficacious and affordable therapies to patients. Consequently, such practices offer tremendous potential in advancing development of cellular therapies. In this vein, the CASMI Translational Stem Cell Consortium (CTSCC) was formed to unite global thought-leaders, producing academically rigorous and commercially practicable solutions to a range of challenges in pluripotent stem cell translation. Critically, the CTSCC research agenda is defined through continuous consultation with its international funding and research partners. Herein, initial findings for all research focus areas are presented to inform global product development strategies, and to stimulate continued industry interaction around biomanufacturing, strategic partnerships, standards, regulation and intellectual property and clinical adoption.
Repairing Damaged Tendon and Muscle: Are Mesenchymal Stem cells and Scaffolds the Answer?
Davies, Benjamin M. , Baboldashti, Nasim Zargar, Hakimi, Osnat , Snelling, Sarah , Morrey, Mark E. , Mouthuy, Pierre‐Alexis , Price, Andrew James , Carr, Andrew Jonathan

Mayo Clinic

Regenerative Medicine | September 2, 2013 | Volume: 8 | Issue: 5 | Pages: 613-630

10.2217/rme.13.55 | PMID 23998754 Get It

Surgical capsular release reduces flexion contracture in a rabbit model of arthrofibrosis
An, Kai‐Nan, Steinmann, Scott P. , Morrey, B.F. , Barlow, Jonathan D. , Hartzler, Robert U. , Abdel, Matthew P. , Morrey, Mark E. , An, Kai‐Nan , Sánchez‐Sotelo, Joaquín

Mayo Clinic

Journal of Orthopaedic Research | May 23, 2013 | Volume: 31 | Issue: 10 | Pages: 1529-1532

10.1002/jor.22385 | PMID 23703948 Get It

ABSTRACTAnimal models of joint contracture may be used to elucidate the mechanisms of arthrofibrosis. Patients with joint contracture commonly undergo surgical capsular release. Previous animal models of joint contracture do not simulate this aspect of arthrofibrosis. We hypothesize that a surgical capsular release will decrease the severity of arthrofibrosis in this rabbit model. A capsular contracture was surgically created in 20 skeletally mature rabbits. Eight weeks later, ten rabbits underwent capsular release, which consisted of elevation of the posterior capsule through a lateral incision and manipulation under anesthesia. Ten rabbits had a sham incision, without release (control group). Immediately after release or sham surgery, extension loss (calculated by subtracting the knee extension angle (degrees) of the operative limb from the nonoperative, contralateral limb) was measured using fluoroscopy. All animals were sacrificed following 16 weeks of postoperative free cage activity. At sacrifice, joint contracture was measured using a custom, calibrated device. The histology of the posterior joint capsule was assessed at sacrifice. All animals survived both operations without complications. Immediately after surgical release or sham surgery, the average extension loss was 129.2 ± 10.7° in the control group versus 29.6 ± 8.2° in the capsular release group (p = 0.0002). Following 16 weeks of remobilization, the average extension loss of the control and capsular release animals were 49.0 ± 12.7° and 36.5 ± 14.2°, respectively (p = 0.035). There were no histological differences between the two groups. In this animal model, a surgical capsular release decreased the extension loss (flexion contracture) immediately after surgery, as well as following sixteen weeks of remobilization. There were no histological changes detected in the posterior joint capsule. © 2013 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 31:1529–1532, 2013